NXTS Nexentis Technologies Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1789192 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.6%
TTM net income YoY-19.7%
TTM EPS YoY-31,123.8%
Revenue 3-yr CAGR-16.6%
Net income 3-yr CAGR—
Margins
Gross margin65.2%
Operating margin-2,119.7%
Net margin-3,187.1%
FCF margin—
EBITDA margin-2,114.4%
Returns
ROE-92.5%
ROA-78.9%
ROIC (approx.)-126.3%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets21.3%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.42x
Accruals ratio-45.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $210,000 |
| Cost of revenue | — | $165,000 |
| Gross profit | — | $45,000 |
| R&D expense | $179,000 | $369,000 |
| SG&A expense | $5.11M | $3.28M |
| Operating income | -$4.23M | -$3.28M |
| Interest expense | — | $16 |
| Pretax income | -$3.61M | -$4.32M |
| Income tax | -$18,000 | — |
| Net income | -$4.00M | -$5.19M |
| EBITDA | -$4.16M | -$3.27M |
| EPS (basic) | -3.54 | -27.74 |
| EPS (diluted) | -8.61 | -27.74 |
| Weighted avg. shares (diluted) | 1.29M | 187,215 |
| Banking | ||
| Net interest income | $0 | -$55,000 |
| Balance sheet | ||
| Cash & equivalents | $3.83M | $2.21M |
| Short-term investments | $239,000 | $307,000 |
| Receivables | $134,000 | $137,000 |
| Inventory | — | $21,000 |
| Current assets | $6.01M | $3.45M |
| PP&E, net | $26,000 | $48,000 |
| Goodwill | $6.29M | — |
| Intangibles | $4.43M | — |
| Total assets | $20.41M | $5.46M |
| Current liabilities | $1.43M | $892,000 |
| Short-term debt | $740,000 | — |
| Total liabilities | $4.67M | $892,000 |
| Shareholders' equity | $16.01M | $4.75M |
| Shares outstanding | 79,504 | 344,741 |
| Cash flow statement | ||
| Operating cash flow | -$3.81M | -$3.42M |
| Capital expenditure | $14,000 | — |
| Free cash flow | -$3.82M | — |
| Investing cash flow | -$3.23M | -$1.89M |
| Financing cash flow | $8.86M | $3.05M |
| Depreciation & amortization | $71,000 | $18,000 |
| Stock-based compensation | $91,000 | $1,000 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.